Ionis Pharmaceuticals Inc. (IONS) is heading in the right direction with an average volume of $1.02M

NFTs Stocks
NFTs Stocks

As on November 23, 2022, Ionis Pharmaceuticals Inc. (NASDAQ: IONS) started slowly as it slid -2.25% to $41.25. During the day, the stock rose to $42.75 and sunk to $41.175 before settling in for the price of $42.20 at the close. Taking a more long-term approach, IONS posted a 52-week range of $25.04-$48.82.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 16.80%. Meanwhile, its Annual Earning per share during the time was 16.50%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 93.60%. This publicly-traded company’s shares outstanding now amounts to $141.95 million, simultaneously with a float of $141.26 million. The organization now has a market capitalization sitting at $5.85 billion. At the time of writing, stock’s 50-day Moving Average stood at $44.42, while the 200-day Moving Average is $39.67.

Ionis Pharmaceuticals Inc. (IONS) Ownership Facts and Figures

Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Ionis Pharmaceuticals Inc.’s current insider ownership accounts for 0.40%, in contrast to 90.70% institutional ownership. According to the most recent insider trade that took place on Sep 08, this organization’s EVP Research sold 460 shares at the rate of 44.55, making the entire transaction reach 20,493 in total value, affecting insider ownership by 19,892. Preceding that transaction, on Jul 15, Company’s Director sold 1,333 for 38.24, making the whole transaction’s value amount to 50,977. This particular insider is now the holder of 18,791 in total.

Ionis Pharmaceuticals Inc. (IONS) Earnings and Revenue Records

If we go through the results of last quarter, which was made public on 6/29/2022, the company posted -$0.74 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -$0.62) by -$0.12. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.78 per share during the current fiscal year.

Ionis Pharmaceuticals Inc.’s EPS increase for this current 12-month fiscal period is 93.60% and is forecasted to reach -2.63 in the upcoming year.

Ionis Pharmaceuticals Inc. (NASDAQ: IONS) Trading Performance Indicators

Let’s observe the current performance indicators for Ionis Pharmaceuticals Inc. (IONS). It’s Quick Ratio in the last reported quarter now stands at 7.50. The Stock has managed to achieve an average true range (ATR) of 1.60. Alongside those numbers, its PE Ratio stands at $711.21, and its Beta score is 0.55. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 6.68. Similarly, its price to free cash flow for trailing twelve months is now 50.72.

In the same vein, IONS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.06, a figure that is expected to reach -0.89 in the next quarter, and analysts are predicting that it will be -2.63 at the market close of one year from today.

Technical Analysis of Ionis Pharmaceuticals Inc. (IONS)

Through scrutinizing the latest numbers posted by the [Ionis Pharmaceuticals Inc., IONS], it can be observed that its last 5-days Average volume of 0.94 million was lower the volume of 1.06 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 5.55% While, its Average True Range was 1.59.


Please enter your comment!
Please enter your name here